checkAd

     141  0 Kommentare PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy - Seite 2

    Contact:
    Crescendo Communications, LLC
    Tel: 212-671-1021
    Email: prfx@crescendo-ir.com

    Lesen Sie auch

    Ilan Hadar
    Chief Executive Officer
    PainReform Ltd.
    Tel: +972-54-5331725
    Email: ihadar@painreform.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy - Seite 2 Remains on track to announce top-line data by mid-2024TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) - PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the …